Pulling SEC filings + quote and writing the call…

Bain Capital Specialty Finance, Inc.
Next earnings Aug 3, 2026 · consensus $0.44 EPS, $65.7M rev
Last earnings +1.5% on 2026-05-12
Cheap externally-managed BDC trading below NAV with a fat dividend, but earnings are sliding and the payout is outrunning operating cash flow.
Price $11.96 · current
Fundamentals and price both look middling — no strong edge either way.
BCSF is an externally-managed middle-market BDC (Advisor is a Bain Capital Credit subsidiary) that has invested ~$9.8B cumulatively since October 2016 in primarily senior secured direct lending — first lien, unitranche, and second lien — to North American, European and Australian middle-market companies ($10–150M EBITDA). The structural appeal is real: as a RIC, it must distribute ≥90% of investment-company taxable income, which is why dividends paid in FY2025 were $146M (+27.6% YoY) — a yield engine on a $11.96 stock with $1.53 in diluted EPS and a P/E of 7.8x. Stockholders' equity of $1.12B on 64.9M shares implies a NAV around ~$17.2/share, and the 10-K explicitly acknowledges the common 'has historically traded below our NAV per share' — i.e., the discount embedded in today's price is a known feature, not a one-off dislocation.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $120M | $105M | $123M | $119M | $98.8M |
| Diluted EPS | $1.86 | $1.63 | $1.91 | $1.85 | $1.53 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting results: directors elected and routine proposals ratified.
Q1'26 earnings release; quarterly dividend declared alongside results.
Q1'26 10-Q: portfolio steady; leverage ~1.38x equity, NAV holding near book.
Preliminary Q1'26 results / dividend declaration ahead of full release.
Proxy: routine director election and auditor ratification, no governance changes.
FY25 10-K: NI -17% to $98.8M, EPS $1.53, dividends $146M exceed earnings.
FY25 10-K: NI -17% to $98.8M, EPS $1.53, dividends $146M exceed earnings.
Q4'25 dividend/results pre-announcement filed.
Entered new material agreement and incurred debt obligation (likely credit facility).
Sources: SEC EDGAR (CIK 0001655050, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/25/2026, 3:03:02 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2026-03-03 | Rusnak-Carlson Sabrina General Counsel | Buy | 2.30K @ $12.55 | $28.9K |
| 2025-03-17 | Richer Clare Stack Director | Buy | 1.53K @ $16.43 | $25.1K |
| 2022-08-10 | Richer Clare Stack Director | Buy | 3.40K @ $14.59 | $49.6K |
| 2022-03-25 | Hough Thomas A. Director | Buy | 6.27K @ $15.94 | $100.0K |
| 2022-03-03 | Richer Clare Stack Director | Buy | 3.09K @ $16.18 | $50.0K |
| 2022-02-25 | Butte Amy Director | Buy | 1.30K @ $15.86 | $20.6K |
| 2021-05-11 | Richer Clare Stack Director | Buy | 1.56K @ $15.90 | $24.9K |
| 2020-12-03 | Ewald Michael A President and CEO | Buy | 4.00K @ $12.52 | $50.1K |
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1044 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.